La gliomatose cérébrale

Sanson, Marc; Napolitano, Massimo; Cartalat‐Carel, Stéphanie; Taillibert, Sophie

doi:10.1016/s0035-3787(05)85020-9

Cited by 8 publications

(21 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, some researchers demonstrated that upfront TMZ treatment was effective for patients with GC [10,12,13]. By using a retrospective case-cohort study, we investigated the efficacy of adjuvant chemotherapy such as TMZ or nitrosourea-based chemotherapy for GC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of adjuvant chemotherapy for gliomatosis cerebri

et al. 2010

View full text Add to dashboard Cite

BackgroundGliomatosis cerebri (GC) is characterized by a diffuse infiltration of tumor cells throughout CNS, however, few details are available about the chemotherapeutic effect on GC. The aim of this study was to investigate its clinical course and to determine the efficacy of chemotherapy for GC.MethodsBetween Jan. 1999 and Dec. 2004, 37 GC patients were diagnosed by biopsy and treated with radiotherapy in a single institution. To determine the efficacy of chemotherapy for GC, we retrospectively reviewed their clinical courses. The study cohort was divided into 2 groups, those with and without receiving post-radiotherapy adjuvant chemotherapy such as temozolomide or nitrosourea-based chemotherapy.ResultsNineteen patients with adjuvant chemotherapy were assigned to the chemotreatment group and 18 with radiotherapy alone were assigned to the control group. Mean survival for chemotreatment group and control group were 24.2 and 13.1 months, respectively (p = 0.045). Time to progression for these groups were 16.0 and 6.0 months, respectively (p = 0.007). Overall review of the clinical course of patients with GC provided that early appearance of new contrast-enhancing lesions within 6 months from the initial diagnosis and higher histological grade were closely associated with poor survival (p < 0.001 and p = 0.008).ConclusionAdjuvant chemotherapy following radiotherapy could prolong the survival in patients with GC. In addition, newly developed contrast-enhanced lesions on the follow-up MR images indicate the progression of GC.

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, chemotherapeutic effects as an adjuvant treatment or first-line treatment are not definitely proved yet [10,12,13]. Here, we present a series of 37 GC patients who underwent radiotherapy for GC.…”

Section: Introductionmentioning

confidence: 99%

Impact of adjuvant chemotherapy for gliomatosis cerebri

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The mitotic index is variable and there is generally no vascular proliferation or necrosis. Expression of glial fibrillary acid protein (GFAP) suggests an astrocytic origin, though in some cases it is scant or absent, with the majority of cases compatible with WHO grade III astrocytoma, but also grade II and IV . Oligodendroglial gliomatosis has also been described.…”

Section: Diagnosismentioning

confidence: 99%

Gliomatosis cerebri: A consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26–27, 2015, Paris, France

Greenfield

Heredia

George

et al. 2016

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Gliomatosis cerebri (GC) is a universally fatal extensive and diffuse infiltration of brain parenchyma by a glial tumor. Many aspects of this phenomenon remain unknown. The First International Gliomatosis cerebri Group Meeting had the following goals: refine the clinical and radiologic diagnostic criteria for GC, suggest appropriate diagnostic procedures, standardize tissue manipulation for histologic and molecular characterization, and prioritize relevant preclinical projects. Also, general treatment recommendations were outlined for the pediatric population. Importantly, this meeting was the starting point for meaningful collaborative international research projects. This review is a consensus summary of discussions shared and conclusions derived from this meeting.

show abstract

“…

…”

mentioning

confidence: 99%

“…Histological diagnosis remains difficult. Finally, gliomatosis poses a specific therapeutic problem compared to other glial tumours due to the toxicity of panencephalic radiotherapy and the impossibility of achieving surgical reduction of the tumour (Sanson et al, 2005). Data from the literature show a median overall survival of 14.5 months, a higher frequency of oligodendroglial forms.…”

mentioning

confidence: 99%

The encephalitic syndrome revealing cerebral gliomatosis in an adolescent

Ahmed¹,

Daoudi²

2020

roneuro

View full text Add to dashboard Cite

Cerebral gliomatosis is a rare glial tumour which is defined by a diffuse and not very destructive infiltration of the encephalon by the glial neoplastic cells in the absence of individualizable tumour mass (Sanson et al., 2005). The clinical and radiological presentation is often misleading and not very specific, and the diagnosis is rarely mentioned. Histological diagnosis remains difficult. Finally, gliomatosis poses a specific therapeutic problem compared to other glial tumours due to the toxicity of panencephalic radiotherapy and the impossibility of achieving surgical reduction of the tumour (Sanson et al., 2005). Data from the literature show a median overall survival of 14.5 months, a higher frequency of oligodendroglial forms. The prognosis is linked to age, functional status, histological grade, oligodendroglial differentiation (Sanson et al., 2005). We report the observation of a gliomatosis occurring in a 14-year-old boy, having presented focal subintral epileptic attacks accompanied by hemiparesis. Flair sequence brain MRI showed a left fronto-temporo-insular hyper signal. The brain biopsy revealed gliomatosis. The evolution was favourable after radiotherapy. Gliomatosis is a diagnosis to be systematically evoked in the presence of a diffuse cerebral affection. Its etiopathogenic mechanism is unknown, and evolution is unpredictable (Millan. BS et al., 2010).

show abstract

La gliomatose cérébrale

Cited by 8 publications

References 45 publications

Impact of adjuvant chemotherapy for gliomatosis cerebri

Impact of adjuvant chemotherapy for gliomatosis cerebri

Gliomatosis cerebri: A consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26–27, 2015, Paris, France

The encephalitic syndrome revealing cerebral gliomatosis in an adolescent

Contact Info

Product

Resources

About